Once lung cancer is suspected on a scan, minimally invasive diagnostic procedures and comprehensive biomarker testing are ...

BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced that WPS Government Health Administrators, ...

Biodesix, Inc. announced a new study published in CHEST Pulmonary Journal reaffirming the effectiveness of its Nodify CDT® blood-based lung nodule test, which assesses seven autoantibodies linked to ...

• Quantitative parameters K trans and V e values of contrast enhanced magnetic resonance imaging (DCE-MRI) showed high diagnostic efficacy for malignant solid solitary pulmonary nodules (SSPNs). • ...

Guardant Health is joining in on the American Lung Association’s (ALA’s) push to raise awareness about lung cancer screening and biomarker testing. The U.S. Preventive Services Task Force recommends ...

Picture this: Your doctor orders an imaging test like a chest X-ray in preparation for an upcoming procedure, and the results show a small white spot in the center of your lungs-a pulmonary or lung ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it has met its targeted enrollment for the NIGHTINGALE trial, which ...

Biodesix, Inc. BDSX recently announced a new post-market clinical validation study, published in CHEST Pulmonary Journal. The study reaffirms the previously established performance of the BDSX’s ...